Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.
NEW YORK/MADRID Eli Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its medicine abemaciclib to standard therapy reduced the risk of disease progression by 46 percent.
Sept 9 An experimental Eli Lilly and Co drug taken with standard therapy reduced the risk of disease progression by 46 percent versus standard therapy alone in women not previously treated for advanced breast cancer, according to interim data from a late stage study presented at a medical meeting.
Quest Diagnostics Inc said on Thursday it will begin using a more precise method of calculating levels of "bad" LDL cholesterol that no longer requires fasting prior to blood draw, a development likely to delight patients who previously had to refrain from eating for up to 12 hours before testing.
Novartis AG on Wednesday won highly anticipated U.S. approval for the first of a new type of potent gene-modifying immunotherapy for leukemia, a $475,000 treatment that marks the start of a potential new treatment paradigm for some cancers.
Scientific instruments maker PerkinElmer Inc on Thursday posted a second-quarter profit that matched expectations and boosted its full-year earnings forecast range with a new midpoint slightly ahead of Wall Street estimates.
Pfizer Inc's chief executive said on Tuesday he would prefer to wait for clarity on U.S. tax reform before engaging in any big deals in order to get a better understanding of any potential acquisition target's value. | Video
NEW YORK Pharmacy benefit manager Express Scripts Holding Co said on Monday it would favor drugmaker Mylan Inc's versions of the EpiPen lifesaving allergy treatment over the allergy auto-injectors of other companies.
Amgen Inc said on Thursday the U.S. Food and Drug Administration granted priority review to the company's request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha.
Celgene Corp rode its flagship multiple myeloma drug Revlimid and a rebound in sales of Otezla for psoriasis to a modestly higher-than-expected second-quarter profit and raised its full-year earnings forecast on Thursday.